Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Engineering T cell receptors to improve cancer immunotherapy
FY 2021-22
Summary
T cell receptor (TCR) gene therapy involves the adoptive transfer of T cells engineered with high-affinity TCRs to induce a clinically effective anti-tumor response. Results of recent clinical trials show that TCR gene therapy is a promising treatment for cancer. TCRs expressed on the surface of T cells consist of alpha and beta chains, which together recognizes cancer peptides or antigens presented by human leukocyte antigens (HLAs) on the surface of cancer cells. We and others previously showed that most, if not all, TCRs exhibit chain centricity, where one chain predominantly determines antigen recognition and the other contributes to modulating TCR affinity for the antigen-HLA complex. By applying the concept of chain centricity, our group previously isolated TCRs that optimally targeted cancer antigens WT1 and MART1. Another important cancer antigen often being investigated is NY-ESO-1. However, the vast majority of clinical trials use TCRs that target NY-ESO-1 peptide presented on HLA-A2 only. This greatly limits anti-NY-ESO-1 TCR gene therapy to only a very small portion of HLA-matched cancer patients.To make anti-NY-ESO-1 TCR gene therapy available to a broader population of cancer patients, we will generate a highly diverse set of TCRs recognizing NY-ESO-1 displayed on another major HLA allele, HLA-B7, by exploiting TCR chain centricity. From this repertoire, we will isolate a TCR with optimal targeting of NY-ESO-1 and minimal toxicity for pre-clinical and clinical studies.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
466701
Name
Wei Xinyu
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Engineering T cell receptors to improve cancer immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive T Cell Therapy; Cancer; Hla-B7; Immunotherapy; Ny-Eso-1; T Cell Receptor Gene Therapy
Abstract
T cell receptor (TCR) gene therapy involves the adoptive transfer of T cells engineered with high-affinity TCRs to induce a clinically effective anti-tumor response. Results of recent clinical trials show that TCR gene therapy is a promising treatment for cancer. TCRs expressed on the surface of T cells consist of alpha and beta chains, which together recognizes cancer peptides or antigens presented by human leukocyte antigens (HLAs) on the surface of cancer cells. We and others previously showed that most, if not all, TCRs exhibit chain centricity, where one chain predominantly determines antigen recognition and the other contributes to modulating TCR affinity for the antigen-HLA complex. By applying the concept of chain centricity, our group previously isolated TCRs that optimally targeted cancer antigens WT1 and MART1. Another important cancer antigen often being investigated is NY-ESO-1. However, the vast majority of clinical trials use TCRs that target NY-ESO-1 peptide presented on HLA-A2 only. This greatly limits anti-NY-ESO-1 TCR gene therapy to only a very small portion of HLA-matched cancer patients.To make anti-NY-ESO-1 TCR gene therapy available to a broader population of cancer patients, we will generate a highly diverse set of TCRs recognizing NY-ESO-1 displayed on another major HLA allele, HLA-B7, by exploiting TCR chain centricity. From this repertoire, we will isolate a TCR with optimal targeting of NY-ESO-1 and minimal toxicity for pre-clinical and clinical studies.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wei, Xinyu
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~